Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2009 - 2026)

Alnylam Pharmaceuticals' Long-Term Deferred Tax history runs 8 years deep, the most recent figure standing at $117.0 million for Q1 2026.

• Quarterly Long-Term Deferred Tax rose 9.08% year-over-year to $117.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.0 million (up 9.08% YoY) and the FY2025 annual result came in at $126.0 million, up 7.8% from the prior year.
• Long-Term Deferred Tax was $117.0 million for Q1 2026 at Alnylam Pharmaceuticals, down from $126.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $126.0 million in Q4 2025 and bottomed at $10.1 million in Q4 2023.
• A 4-year average of $97.1 million and a median of $107.2 million in 2025 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax jumped 1056.94% — and 2025, when it gained 7.8%.
• Alnylam Pharmaceuticals' Long-Term Deferred Tax stood at $10.1 million in 2023, then soared by 1056.94% to $116.9 million in 2024, then advanced by 7.8% to $126.0 million in 2025, then decreased by 7.16% to $117.0 million in 2026.
• Business Quant data shows ALNY's Long-Term Deferred Tax at $117.0 million in Q1 2026, $126.0 million in Q4 2025, and $98.6 million in Q3 2025.